Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Kavanagh, Kimberley ^a   Sinka, Katy ^b   Cuschieri, Kate ^c   Love, John ^b   Potts, Alison ^b   Pollock, Kevin G J ^b   Cubie, Heather ^e   Donaghy, Martin ^b   Robertson, Chris ^a,b,d  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b HEALTH PROTECTION SCOTLAND   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Human papilloma virus; Multiple infections; Prevalence; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CROSS PROTECTION; CYTOLOGY; DEMOGRAPHY; DRUG MONITORING; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN TISSUE; PAPILLOMAVIRUS INFECTION; PREVALENCE; RURAL AREA; UNITED KINGDOM; URINALYSIS; WART VIRUS; EPIDEMIOLOGY; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; VIROLOGY; YOUNG ADULT;

ADULT; FEMALE; GENOTYPE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; SCOTLAND; YOUNG ADULT;

EID: 84887037710     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-519     Document Type: Article

References (23)

1. Cuschieri K, Brewster DH, Williams ARW, Millian D, Murray G, Nicoll S, Imrie J, Hardie A, Graham C, Cubie HA. Distribution of HPV types associated with cervical cancers in Scotland and implications for the impact of HPV vaccines. Br J Cancer 2010, 102:930-932. 10.1038/sj.bjc.6605556, 2833249, 20145611.
2. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621-632. 10.1002/ijc.22527, 17405118.
3. Garland SM, Brotherton JM, Condon R, McIntyre PB. Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med 2011, 13:104.
4. ISD: Scottish cervical screening programme statistics 2012-13 https://isdscotland.scot.nhs.uk/Health-Topics/Cancer/Publications/2013-08-27/2013-08-27-Cervical-Screening-report.pdf?30622500182.
5. Potts A, Sinka K, Love J, Gordon R, McLean S, Malcolm W, Ross D, Donaghy M. High uptake of HPV immunisation in Scotland - perspectives on maximising uptake. Euro Surveill 2013, 18:e20593.
6. Sinka K, Kavanagh K, Gordon R, Love J, Potts A, Donaghy M, Robertson C. Introduction and sustained high coverage of adolescent HPV vaccine in Scotland. J Epidemiol Community Health 2013, In press.
7. National records of Scotland: 2011 census: first results on population estimates for Scotland - release 1A http://www.scotlandscensus.gov.uk/documents/censusresults/release1a/rel1asb.pdf.
8. Sinka K, Lacey M, Robertson C, Kavanagh K, Cuschieri K, Nicholson D, Donaghy M. Acceptability and response to a postal survey using self-taken samples for HPV vaccine impact monitoring. Sex Transm Infect 2011, 87:548-552. 10.1136/sextrans-2011-050211, 21990427.
9. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V, WHO International Agency for research on cancer Monograph working Group A review of human carcinogens -part B: biological agents. Lancet Oncol 2009, 10:321. 10.1016/S1470-2045(09)70096-8, 19350698, WHO International Agency for research on cancer Monograph working Group.
10. Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M, HPV PATRICIA Study Group Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110. 10.1016/S1470-2045(11)70287-X, 22075170, HPV PATRICIA Study Group.
11. Deville JE, Sarndal C, Sautor O. Generalized raking procedures in survey sampling. J Am Stat Assoc 1993, 88:1013-1020.
12. Cuschieri K, Nandwani R, McGough P, Cook F, Hogg L, Robertson C, Cubie H. Urine testing as a surveillance tool to monitor the impact of HPV immunization programs. J Med Virol 2011, 83:1983-1987. 10.1002/jmv.22183, 21915874.
13. R Development Core Team R A language and environment for statistical computing Vienna, Austria: R Foundation for Statistical Computing, http://www.R-project.org/, R Development Core Team R.
14. Lumley T. Analysis of complex survey samples. J State Soft 2004, 9:1-19.
15. Howell-Jones R, de Silva N, Akpan M, Oakeshott P, Carder C, Coupland L, Sillis M, Mallinson H, Ellis V, Frodsham D, Robinson TI, Gill ON, Beddows S, Soldan K. Prevalence of human papillomavirus (HPV) infections in sexually active adolescents and young women in England, prior to widespread HPV immunisation. Vaccine 2012, 30:3867-3875. 10.1016/j.vaccine.2012.04.006, 22516212.
16. Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM, FUTURE I and II Study Group Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012, 344:1401. FUTURE I and II Study Group.
17. Oakeshott P, Aghaizu A, Reid F, Howell-Jones R, Hay PE, Sadiq ST, Lacey CJ, Beddows S, Soldan K. Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study. BMJ 2012, 344:e4168. 10.1136/bmj.e4168, 3382227, 22730542.
18. Aicken CRH, Estcourt CS, Keane F, Brook G, Ward H, Low N, Rait G, White PJ, Cassell JA, Mercer CH. Geographical variations in sexual behaviour of heterosexual GUM patients: myth or reality?. Intl J STD AIDS 2011, 22(Suppl 1):013.
19. Westwood J, Mullan B. Young people and sexual risk-taking behaviour in central England. Sex Health 2009, 6:135-138. 10.1071/SH08090, 19457293.
20. O'Leary MC, Sinka K, Robertson C, Cuschieri K, Lyman R, Lacey M, Potts A, Cubie HA, Donaghy M. HPV type-specific prevalence using a urine assay in unvaccinated male and female 11- to 18-year olds in Scotland. Br J Cancer 2011, 104:1221-1226. 10.1038/bjc.2011.30, 3068489, 21343934.
21. Stanczuk GA, Kay P, Allan B, Chirara M, Tswana SA, Bergstrom S, Sibanda EN, Williamson AL. Detection of human papillomavirus in urine and cervical swabs from patients with invasive cervical cancer. J Med Virol 2003, 71:110-114. 10.1002/jmv.10456, 12858416.
22. Verdenius I, Groner JA, Harper DM. Cross protection against HPV might prevent type replacement. Lancet Infect Dis 2013, 13:195.
23. Nielsen A, Kjaer SK, Munk C, Iftner T. Type-specific HPV infection and multiple HPV types: prevalence and risk factor profile in nearly 12,000 younger and older Danish women. Sex Transm Dis 2008, 35:276-282. 10.1097/OLQ.0b013e31815ac5c7, 18091564.